|
19 Apr 2025 |
SRF
|
Consensus Share Price Target
|
2990.40 |
2725.28 |
- |
-8.87 |
hold
|
|
|
|
|
01 Feb 2024
|
SRF
|
IDBI Capital
|
2990.40
|
2770.00
|
2308.45
(29.54%)
|
Target met |
Buy
|
|
|
|
|
30 Nov 2023
|
SRF
|
IDBI Capital
|
2990.40
|
2913.00
|
2412.50
(23.95%)
|
|
Buy
|
|
|
|
|
31 Oct 2023
|
SRF
|
Edelweiss
|
2990.40
|
2530.00
|
2195.30
(36.22%)
|
Target met |
Buy
|
|
|
Weak H1, recovery expected in H2FY24
|
|
30 Oct 2023
|
SRF
|
Motilal Oswal
|
2990.40
|
2000.00
|
2181.40
(37.09%)
|
|
Neutral
|
|
|
|
|
30 Oct 2023
|
SRF
|
ICICI Securities Limited
|
2990.40
|
2100.00
|
2181.40
(37.09%)
|
Target met |
Hold
|
|
|
SRF’s Q2FY24 print for its chemical business (EBIT down 32.8% YoY) was below our expectations – hurt by lower sales in ref-gas and weakness in specialty sales from destocking. Despite this, SRF expects some growth in specialty chemicals revenue for FY24 and anticipates revival in ref-gas revenue in H2FY24E, as it has started to contract volumes in US for CY24 HFC quota.
|
|
30 Oct 2023
|
SRF
|
Prabhudas Lilladhar
|
2990.40
|
2156.00
|
2181.40
(37.09%)
|
Target met |
Hold
|
|
|
|
|
26 Jul 2023
|
SRF
|
IDBI Capital
|
2990.40
|
2913.00
|
2144.30
(39.46%)
|
|
Buy
|
|
|
|
|
26 Jul 2023
|
SRF
|
Edelweiss
|
2990.40
|
2570.00
|
2144.30
(39.46%)
|
Target met |
Buy
|
|
|
Weak earnings; recovery expected in H2FY24
|
|
25 Jul 2023
|
SRF
|
ICICI Securities Limited
|
2990.40
|
2135.00
|
2164.10
(38.18%)
|
Target met |
Hold
|
|
|
SRF’s Q1FY24 print for its chemical business (EBIT down 11.6% YoY) was below our expectations and was hurt from lower sales in ref-gas (both volume and price declined) while specialty sales were hurt from destocking. Company anticipates specialty chemicals sales to be impacted over the next few quarters though it has not seen any order cancellation, which implies steady underlying demand.
|
|
27 Jun 2023
|
SRF
|
Motilal Oswal
|
2990.40
|
2580.00
|
2308.35
(29.55%)
|
Target met |
Neutral
|
|
|
|